Show simple item record

dc.contributor.authorWilding, CP
dc.contributor.authorElms, ML
dc.contributor.authorJudson, I
dc.contributor.authorTan, A-C
dc.contributor.authorJones, RL
dc.contributor.authorHuang, PH
dc.date.accessioned2019-11-06T10:11:08Z
dc.date.issued2019-11-13
dc.identifier.citationExpert review of anticancer therapy, 2019, 19 (11), pp. 971 - 991
dc.identifier.issn1473-7140
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3402
dc.identifier.eissn1744-8328
dc.identifier.doi10.1080/14737140.2019.1686979
dc.description.abstractIntroduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes including proliferation, migration, and apoptosis. As such, targeting these proteins with small molecule tyrosine kinase inhibitors (TKI) has led to significant advances in the treatment of a number of cancer types.Areas covered: Soft tissue sarcomas (STS) are a heterogeneous and challenging group of rare cancers to treat, but the approval of the TKI pazopanib for the treatment of advanced STS demonstrates that this class of drugs may have broad utility against a range of different sarcoma histological subtypes. Since the approval of pazopanib, a number of other TKIs have entered clinical trials to evaluate whether their activity in STS matches the promising results seen in other solid tumors. In this article, we review the emerging role of TKIs in the evolving landscape of sarcoma treatment.Expert opinion: As our biological understanding of response and resistance of STS to TKIs advances, we anticipate that patient management will move away from a 'one size fits all' paradigm toward personalized, multi-line, and patient-specific treatment regimens where patients are treated according to the underlying biology and genetics of their specific disease.
dc.formatPrint-Electronic
dc.format.extent971 - 991
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectSarcoma
dc.subjectSulfonamides
dc.subjectPyrimidines
dc.subjectProtein Kinase Inhibitors
dc.subjectDrug Resistance, Neoplasm
dc.subjectProtein-Tyrosine Kinases
dc.subjectPrecision Medicine
dc.titleThe landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737140.2019.1686979
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-11-13
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfExpert review of anticancer therapy
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume19
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trialsen_US
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorWilding, Christopheren
dc.contributor.icrauthorElms, Marken
dc.contributor.icrauthorHuang, Paulen
dc.contributor.icrauthorJudson, Ianen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0